Alferon LDO (Human Leukocyte Derived) is an experimental low-dose, oral liquid formulation of Natural Alpha Interferon, and, like Alferon N Injection, should not cause antibody formation, which is a known problem with recombinant interferon.
Alferon LDO, an experimental immunotherapeutic, is believed to work by stimulating an immune cascade response in the cells of the mouth and throat, enabling it to support systemic immune response through the entire body by absorption through the oral mucosa.
Oral administration of Alferon LDO, with its affordability, low toxicity, expected non-production of antibodies, and broad range of potential bioactivity, would prove to be a major treatment to prevent viral diseases including influenza, the company claimed.
Hemispherx Biopharma chairman and CEO William A Carter said with the issuance of new patents, the company now plans advance this program forward with clinical studies in the US and in other parts of the world.
"Oral administration of Alferon(R) LDO, an experimental therapeutic, with its ease of administration, has the potential to become a significant therapeutic advance for the treatment or prevention of viral diseases," Carter added.